Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Flowers Foods just reported earnings and got a modest bounce, but the short position rebuilt sharply in the days after — the central tension heading into the back half of August is whether that rebuild reflects fresh conviction or simply noise around the print.
Short interest jumped 5.8% on the week to 21.7% of the free float, reversing the gentle drift lower that had characterised the pre-earnings period. The move from 43.5 million shares on August 24 to 45.9 million by August 27 is the sharpest weekly increase in the trailing 30-day window. That is a meaningful shift in posture. The ORTEX short score has climbed steadily throughout the week, reaching 74.1 — its highest reading in the history shown and up from 70.7 just two weeks ago. Bears are not covering. They are adding. The lending market does nothing to constrain them: availability runs at 118%, meaning more shares remain available to borrow than are currently borrowed, and cost to borrow is just 0.55%. There is no friction and no squeeze pressure. What changed from prior notes is the direction — SI was drifting lower into the print, and now it is moving the other way.
The post-earnings price action tells a different story from the positioning. FLO gained 2.5% on the day of results (August 21) and has added another 2.2% on the week, closing at $7.10. That is a stock recovering modestly while shorts are rebuilding — a divergence worth watching. For context, peers GIS gained 4% on the week and KHC added 0.5%, while CPB and CAG both slipped around 2%. FLO is not lagging the group this week, which makes the simultaneous short rebuild more pointed — bears are not simply following the sector lower.
The Street remains uniformly cautious. The most recent analyst action came from Stephens & Co. on August 24, lowering its target to $6 from $8 while holding an Equal-Weight rating — a cut to below the current price of $7.10, which is a stark signal. Deutsche Bank set a $7 target earlier in the year, essentially at current levels. The mean price target of $7.90 implies limited upside, and the direction of revisions has been consistently down since at least early 2025. The bear case is well-documented: Walmart concentration, private-label pressure, input cost headwinds, and earnings that have missed expectations. The bull case rests on a healthy balance sheet and dividend yield — but the dividend data on file is stale (last recorded in 2022), so that pillar deserves scrutiny. EV/EBITDA at roughly 8x and price-to-book near 1.1x look undemanding, and the EPS forward-year increase factor scores in the 73rd percentile, though near-term momentum on estimates scores in the bottom decile. Valuation is not obviously stretched, but sentiment is clearly poor.
One institutional development stands out. BlackRock added 14.6 million shares in its most recent reported period ending July 31, lifting its holding to 34.6 million shares — 16.3% of shares outstanding. That is a large incremental buy from the largest holder. Against that, the CFO bought $37,500 worth of stock in early June at $7.51. Neither is a ringing endorsement of near-term momentum, but both suggest the stock is not being abandoned by longer-duration holders even as shorts rebuild.
What to watch next: the ORTEX short score approaching 75 from below, whether availability begins to tighten as the rebuilt short position competes for borrows, and whether the Stephens $6 target draws any response from other analysts covering the name ahead of the November earnings event.
See the live data behind this article on ORTEX.
Open FLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
